Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
India produces 60% of the world’s vaccine
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Lupin will provide five lakh LupiSafe hand sanitizers to policemen and frontline workers deployed at strategic locations
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Subscribe To Our Newsletter & Stay Updated
